Sanofi Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Olivier Charmeil

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	4.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.9yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Olivier Charmeil (62 yo)

less than a year

Amtszeit

Mr. Olivier Charmeil serves as an Executive Vice President of General Medicines at Sanofi and has been its Interim Chief Executive Officer since February 17, 2026 and served as its Head of General Medicine...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Olivier Charmeil	Interim CEO & Executive VP of General Medicines	less than a year	keine Daten	keine Daten
François-Xavier Roger	Executive VP & CFO	1.9yrs	keine Daten	keine Daten
Madeleine Roach	Executive VP & Head of Business Operations	2.4yrs	keine Daten	keine Daten
Thomas Larsen	Head of Investor Relations & General Medicines	2.2yrs	keine Daten	keine Daten
Roy Papatheodorou	Executive VP & General Counsel	4.1yrs	keine Daten	keine Daten
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	21.6yrs	keine Daten	keine Daten
Natalie Bickford	Executive VP & Chief People Officer	5.6yrs	keine Daten	keine Daten
Fabrizio Gaudi	Head of Austrian	7.2yrs	keine Daten	keine Daten
Erik Wallström	Head of Therapeutic Area - Neurology Development	no data	keine Daten	keine Daten
Thomas Triomphe	Executive Vice President of Vaccines	8.2yrs	keine Daten	keine Daten
Karin Knobe	TA Head of Rare Diseases & Rare Blood Disorders Development	no data	keine Daten	keine Daten
Pablo Sardi	TA Head of Rare & Neurologic Diseases Research	no data	keine Daten	keine Daten

4.1yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: SNYN.FDas Führungsteam des Unternehmens gilt als erfahren (4.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jean-François Dehecq	Honorary Chairman	15.8yrs	€4.71m	keine Daten
Serge Weinberg	Honorary Chairman	2.8yrs	€324.96k	keine Daten
Patrick Kron	Independent Director	11.8yrs	€233.50k	0.000080% $ 85.7k
Lise Kingo	Independent Director	5.9yrs	€162.00k	0.000080% $ 85.7k
Frederic Oudea	Independent Chairman	2.8yrs	€884.84k	0.000080% $ 85.7k
Rachel Duan	Independent Director	5.9yrs	€151.00k	0.000080% $ 85.7k
Carole Ferrand	Independent Director	3.8yrs	€208.75k	0.000080% $ 85.7k
Barbara Lavernos	Director	4.9yrs	€162.00k	0.000080% $ 85.7k
Clotilde Delbos	Independent Director	1.9yrs	€197.75k	0.000080% $ 85.7k
Emile Voest	Independent Director	3.8yrs	€186.75k	0.000080% $ 85.7k
Christophe Babule	Director	7.1yrs	€156.50k	0.000080% $ 85.7k
Wolfgang Laux	Employee Representative Director	4.9yrs	€129.00k	keine Daten

4.9yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: SNYN.FDie Vorstandsmitglieder gelten als erfahren (4.9 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/06 22:07
Aktienkurs zum Tagesende	2026/03/06 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, mit dem dieser Bericht erstellt wurde, sind auf unserer Github-Seite verfügbar. Außerdem bieten wir Anleitungen zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sanofi wird von 50 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Sanofi, Annual General Meeting, Apr 30, 2025

Sanofi Announces Board Changes

Recent updates

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Steriles Manufacturing Site in Ridgefield, New Jersey of Sanofi (ENXTPA:SAN).

Sanofi Announces the Us Food and Drug Administration Approves Wayrilz (Rilzabrutinib) in US as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi Confirms Earnings Guidance for the Year 2025

Sanofi's Sarclisa Approves in the EU for the Treatment of Transplant-Efficient Newly Diagnosed Multiple Myeloma

Sanofi Announces BEYFORTUS Reduced Hospital and Doctor Visits for RSV Disease in Babies by 87%

Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion.

Sanofi (ENXTPA:SAN) completed the acquisition of Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC.

Sanofi's Sar446597 Earns Fast Track Designation in the US for Geographic Atrophy Due Toage-Related Macular Debutation

Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Sanofi Accelerates Global Shipping of Beyfortus to Prepare Healthcare Providers Months Ahead of 2025-2026 RSV Season

American Society of Clinical Oncology Announces New Sarclisa Data Support Subcutaneous Administration with On-Body Injector

Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Sanofi (ENXTPA:SAN) entered into a definitive merger agreement to acquire Vigil Neuroscience, Inc. (NasdaqGS:VIGL) for approximately $380 million.

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Clayton, Dubilier & Rice Fund XII a fund managed by Clayton, Dubilier & Rice, LLC acquired 50% stake in Opella Healthcare Group SAS from Sanofi (ENXTPA:SAN) for around €10 billion.

Sanofi's Respiratory Pipeline Advances with New Data in Asthma and Plans for New Clinical Studies in COPD

Sanofi Announces Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on disability Progressive Forms

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Sanofi Announces Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis

Sanofi Adopts FDA-Selected Flu Strains to Ensure Readiness for the 2025-26 Flu Season

Sanofi, Annual General Meeting, Apr 30, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Sanofi Announces New Duvakitug Data Reinforce Best-In-Class Potential in Ulcerative Colitis and Crohn's Disease

Sanofi Announces Sarclisa Approval in Japan for Patients with Newly Diagnated Multiple Myeloma

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Sanofi Announces Update on E.Mbrace Phase 3 Clinical Study

Sanofi Reports Consolidated Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2024

Sanofi Announces Sarclisa Approval in the EU as the First Anti-CD38 Therapy in Combination with Standard-Of-Care VRd to Treat Transplant-ineligible Newly Diagnated Multiple Myeloma

Sanofi Announces Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Sanofi Announces Board Changes

Sanofi Announces Two Combination Vaccine Candidates for Prevention of Influenza and COVID-19 Granted Fast Track Designation in the US

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale